A peptide pill and a non-peptide pill
Until 2026 there was one GLP-1 tablet on the market: Rybelsus, oral semaglutide. Semaglutide is a peptide, and peptides do not survive the stomach, so Rybelsus only works because each tablet pairs the drug with salcaprozate sodium (SNAC), an absorption enhancer, and because the label wraps it in strict rules. Even then, the label puts absolute bioavailability at roughly 0.4% to 1%.
Orforglipron is Eli Lilly's answer: a small synthetic molecule that switches on the same GLP-1 receptor but is not a peptide at all. It is absorbed like an ordinary tablet. The US FDA approved it as Foundayo on 1 April 2026 for chronic weight management.
The two have now been compared directly in a 52-week trial. That, plus the difference in how they are taken, is what this page covers. For the general question of why oral peptides are hard, see oral vs injectable peptides.
Side by side
| Orforglipron (Foundayo) | Oral semaglutide Stocked locally (Rybelsus) | |
|---|---|---|
| Molecule | Small molecule, non-peptide | Peptide plus SNAC absorption enhancer |
| Food and water rules | With or without food, any time of day | Empty stomach, no more than 4 oz plain water, wait 30 minutes before eating or other medicines |
| Half-life | About 29 to 49 hours | About 1 week (same molecule as injected semaglutide) |
| US approvals | Chronic weight management (April 2026); diabetes filing under way | Type 2 diabetes |
| Pivotal weight trial | ATTAIN-1: 11.2% at 36 mg vs 2.1% placebo, 72 weeks | OASIS 1 (50 mg, not marketed): 15.1% vs 2.4%, 68 weeks |
| Head-to-head, HbA1c at 52 weeks | Down 1.71 (12 mg), 1.91 (36 mg) | Down 1.23 (7 mg), 1.47 (14 mg) |
| Head-to-head, GI adverse events | 59% and 58% | 37% and 45% |
| Head-to-head, stopped for adverse events | 9% and 10% | 4% and 5% |
| FDA Philippines | No registration identified | No verified PH price; check the FDA PH portal |
The direct trial: ACHIEVE-3
Published in The Lancet in February 2026, ACHIEVE-3 randomised 1,698 adults with type 2 diabetes inadequately controlled on metformin to orforglipron 12 or 36 mg or oral semaglutide 7 or 14 mg, one tablet a day for 52 weeks, at 131 sites in Argentina, China, Japan, Mexico and the US. It was open label. The primary question was non-inferiority on HbA1c, with superiority tested afterward.
From a baseline HbA1c of 8.3%, using the estimand that counts everyone regardless of whether they stayed on treatment:
- Orforglipron: down 1.71 points on 12 mg and 1.91 on 36 mg.
- Oral semaglutide: down 1.23 on 7 mg and 1.47 on 14 mg.
Non-inferiority was met and both orforglipron doses were superior to both semaglutide doses, including the low orforglipron dose against the high semaglutide dose (a difference of 0.24 points). Lilly's release on the same paper reports greater weight loss on orforglipron as well; the Lancet abstract does not give the weight figures, so this page does not quote them.
The cost showed up in tolerability. Gastrointestinal events, mostly mild to moderate, were reported by 59% and 58% on orforglipron versus 37% and 45% on semaglutide. Discontinuation for adverse events was 9% and 10% versus 4% and 5%. Mean pulse rate rose 3.7 and 4.7 beats per minute on orforglipron versus 1.0 and 1.5 on semaglutide. Four deaths occurred, two in each drug group's arms, in a year-long trial of people with diabetes.
One reading of these numbers is that orforglipron simply delivered more GLP-1 receptor activation, with more effect and more side effect. The trial cannot say whether an oral semaglutide dose above 14 mg would have closed the gap.
Each drug's own trials
ATTAIN-1 (2025) tested orforglipron for obesity in 3,127 adults without diabetes over 72 weeks. Mean weight change was 7.5%, 8.4% and 11.2% on 6, 12 and 36 mg, against 2.1% on placebo. On 36 mg, 54.6% lost at least 10% and 18.4% lost at least 20%. Discontinuation for adverse events ran from 5.3% to 10.3% versus 2.7%. ACHIEVE-1 (2025) in 559 adults with early type 2 diabetes found HbA1c falls of 1.24 to 1.48 points over 40 weeks and weight loss of up to 7.6% on 36 mg.
PIONEER 1 (2019) is the equivalent for Rybelsus in diabetes: 703 adults on diet and exercise alone, 26 weeks, HbA1c placebo-adjusted falls of 0.6, 0.9 and 1.1 points on 3, 7 and 14 mg, and weight loss of 2.3 kg on 14 mg. OASIS 1 (2023) shows what oral semaglutide can do at a much higher dose: 50 mg daily in 667 adults without diabetes produced 15.1% weight loss versus 2.4% on placebo at 68 weeks, with gastrointestinal events in 80%. That 50 mg product is not what Rybelsus is; it shows the peptide pill's ceiling is higher than its marketed dose.
Read together, orforglipron's obesity result (11.2%) sits below injectable semaglutide's STEP 1 result (14.9%) and below oral semaglutide 50 mg, while its head-to-head diabetes result beats marketed Rybelsus. Its advantage is being a normal tablet, not a bigger effect.
The fasting rules, in practice
The Rybelsus label is specific: take it at least 30 minutes before the first food, drink or other oral medicine of the day, with no more than 4 ounces of plain water, swallowed whole. Less waiting, or taking it with anything else, lowers absorption; waiting longer raises it. For someone with a Manila commute and a morning coffee, that is a real constraint, and it is the kind of constraint that decides whether a daily drug is taken at all.
The Foundayo label removes it. The tablet can be taken with or without food, at any time of day. That is the whole argument for a non-peptide GLP-1, and ACHIEVE-3 suggests it does not come at the cost of effect.
Side effects reported
Both carry the GLP-1 class profile: nausea, constipation, diarrhoea and vomiting, concentrated during escalation. Both labels carry the boxed warning on thyroid C-cell tumours seen in rodents and warnings on pancreatitis and gallbladder disease. The Foundayo label adds a warning to use a barrier contraceptive for 30 days after starting and after each dose increase, because it can reduce oral contraceptive absorption. The side effect management guide covers the class in detail.
Status in the Philippines
No FDA Philippines registration for orforglipron or Foundayo had been identified as of September 2026, so it cannot legally be sold here yet; Lilly says it has filed in more than 40 countries. Rybelsus is a Novo Nordisk product, but no verified Philippine pharmacy price exists for it and this site does not assert one. Any tablet sold locally under either name outside a registered pharmacy chain is unregistered product, and as a pill rather than a peptide vial it carries the same identity questions as any unregulated tablet.
The GLP-1 medicines that are registered and on pharmacy shelves are injectable: Ozempic, Wegovy, Mounjaro, Victoza and Saxenda. Prescribing belongs with a licensed Philippine physician. Current pen prices are on cost reality in the Philippines, and the injectable comparison is on semaglutide vs liraglutide.
Storage
Both are room-temperature tablets: the Rybelsus label says 20 to 25°C with excursions to 30°C allowed, in the original bottle to protect from moisture, and the Foundayo label is similar. Manila humidity and rooms above 30°C are the practical problems, so a cool interior cupboard beats a bathroom shelf, a bag or a car.
